As federal and state lawmakers increasingly look to transparency as a way to stem drug price increases, the generic drug trade group has joined with the brand and biotech groups in opposition to a Maryland drug pricing bill, albeit for different reasons. The bill would require both extensive disclosures for any drug with a Wholesale Acquisition Cost of $2,500 or more annually or per course of treatment, as well as notification of expected price hikes. The generic drug industry, which...